欧洲五个试点地区前列腺癌筛查的MRI能力评估
该研究评估了PRAISE-U项目中欧洲五个试点地区(立陶宛、波兰、爱尔兰及西班牙两个地区)的前列腺癌筛查MRI能力与准备情况,内容包括MRI类型、等待时间、诊断质量、放射科医生经验和转诊路径。所有试点地区均在活检前整合了多参数MRI和双参数MRI进行风险分层,各试点在MRI用于风险分层方面表现一致且诊断质量高,但设施基础设施、放射科医生专业知识和MRI方案存在差异。
要点
- 所有试点地区均在活检前使用多参数或双参数MRI进行风险分层。
- 各试点MRI用于风险分层的诊断质量高,使用一致。
- 设施、放射科医生专业知识和MRI方案存在差异,反映不同医疗体系。
核心结论
- 各试点地区在MRI用于风险分层方面表现一致且诊断质量高,但设施基础设施、放射科医生专业知识和MRI方案存在差异,反映不同医疗体系。
研究设计与样本
- 评估欧洲五个试点实施地区(立陶宛、波兰、爱尔兰及西班牙Manresa和Galicia两个地区)MRI能力与准备情况的研究,数据包括MRI类型、等待时间、诊断质量、放射科医生经验和转诊路径。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Recognizing prostate cancer (PCa) as a significant public health challenge, the European Union, in 2022, recommended for organized screening programs incorporating PSA testing with MRI for risk stratification. This study assessed the MRI capacity and readiness of five pilot implementation sites in Europe within the PRostate cancer Awareness and Initiative for Screening Europe (PRAISE-U) project: Lithuania, Poland, Ireland, and two Spanish regions (Manresa and Galicia). Data included MRI types, waiting times, diagnostic quality, radiologist experience, and referral pathways. All pilot sites integrated multiparametric MRI (mpMRI) and biparametric MRI (bpMRI) for risk stratification before prostate biopsy. MRI capacity and readiness for PCa screening across pilot implementation sites demonstrate consistent use of MRI for risk stratification and high diagnostic quality. Some difference in facility infrastructure, radiologist's expertise, and MRI protocols reflect diverse healthcare systems. Future comparison of bpMRI and mpMRI in real-time screening settings will provide critical evidence for scaling the program. Standardizing MRI protocols and PSA assays across pilot sites is essential to ensure quality and consistency. The PRAISE-U project will deliver valuable insights into the feasibility and scalability of MRI-based PCa screening programs across Europe.
引用
- Singh D, Chandran A, Panebianco V, et al. MRI capacity assessment for prostate cancer screening in five sites of Europe. Eur J Radiol. 2025. PMID: 40527099. doi:10.1016/j.ejrad.2025.112235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。